CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
CEL-SCI Shares Are Trading Higher After the Company Announced Results From a Bias Analysis Conducted for Its Concluded Phase 3 Study of Multikine. Multikine Cut the 5-year Risk of Death by Half Compared to Control in Its Target Population.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated